ASSEMBLY BIOSCIENCES
Assembly Biosciences, Inc. is a public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral biotherapeutics designed to address diseases associated with the microbiome. Assembly‘s HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome p... rogram consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform is in development for the treatment of C. difficile infections. Assembly is also developing additional microbiome product candidates.
ASSEMBLY BIOSCIENCES
Industry:
Biotechnology Health Care
Founded:
2005-01-01
Address:
Carmel, Indiana, United States
Country:
United States
Website Url:
http://www.assemblybio.com
Total Employee:
51+
Status:
Active
Contact:
+1 646-706-5208
Email Addresses:
[email protected]
Total Funding:
337.8 M USD
Technology used in webpage:
Domain Not Resolving HSTS IPv6 Microsoft COVID-19 DigiCert SSL AWS Global Accelerator Akamai Hosted Thawte SSL CenturyLink
Similar Organizations
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Armistice Capital
Armistice Capital investment in Post-IPO Equity - Assembly Biosciences
Gilead Sciences
Gilead Sciences investment in Post-IPO Equity - Assembly Biosciences
Gilead Sciences
Gilead Sciences investment in Post-IPO Equity - Assembly Biosciences
Key Employee Changes
Official Site Inspections
http://www.assemblybio.com Semrush global rank: 417.17 K Semrush visits lastest month: 85.54 K
- Host name: 73.38.148.146.bc.googleusercontent.com
- IP address: 146.148.38.73
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Assembly Biosciences"
Assembly Biosciences Announces Program Reprioritization and ...
Jul 20, 2022 Assembly Bio will align the organization to reflect its refocused pipeline. The company workforce will be reduced by approximately 30%, to approximately 70 full-time …See details»
Assembly Biosciences - Crunchbase Company Profile
Contact Email [email protected] Phone Number +1 646-706-5208 Assembly Biosciences, Inc. is a public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral …See details»
Assembly Biosciences, Inc. | LinkedIn
Assembly Biosciences, Inc. | 5,871 followers on LinkedIn. Passionate about making a profound impact on patients’ lives | Assembly Biosciences is a biotechnology company dedicated to the ...See details»
Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief …
Nov 8, 2023 “We are excited to have Dr. Gaggar join Assembly Bio’s leadership team at an incredibly important time for the organization,” said Jason Okazaki, chief executive officer and …See details»
Assembly Biosciences Reports Third Quarter 2022 Financial Results …
For more information, visit assemblybio.com. Forward-Looking Statements The information in this press release contains forward-looking statements that are subject to certain risks and …See details»
Corporate Governance - Assembly Biosciences, Inc.
The Board of Directors of Assembly Biosciences, Inc. sets high standards for the company's employees, officers and directors. Implicit in this philosophy is the importance of sound …See details»
Press Release - Assembly Biosciences, Inc.
Oct 5, 2022 Jason’s strategic vision, leadership skills and respect within and outside of our organization will ensure we continue to advance the company’s mission of bringing these …See details»
Assembly Biosciences, Inc. (ASMB) Company Profile & Overview
Dec 17, 2010 Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes …See details»
Assembly Biosciences Announces Appointment of John …
Aug 7, 2019 During his nine years at Gilead he led the organization in the successful filing of numerous New Drug Applications (NDAs) across multiple therapeutic areas including the …See details»
Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief …
Nov 8, 2023 AT&T price target raised to $26 from $24 at Citi. Citi raised the firm’s price target on AT&T to $26 from $24 and keeps a Buy rating on the shares ahead of the investor day on …See details»
Assembly Bio Announces Retirement of John G. McHutchison, AO, …
Oct 5, 2022 Dr. McHutchison will continue to provide strategic counsel as board member and chairman of the Science & Technology Committee of the boardSOUTH SAN FRANCISCO, …See details»
Assembly Biosciences Announces Management Transition
“I look forward to advancing these exciting research programs and to collaborate across the organization in executing our important mission to deliver a potential finite duration therapy for …See details»
Assembly Bio Announces Key Promotions to Leadership Team
For more information, visit assemblybio.com. Forward-Looking Statements The information in this press release contains forward-looking statements that are subject to certain risks and …See details»
Assembly Biosciences Announces Changes to Senior Leadership …
May 2, 2019 Mr. Small stated, “On behalf of the entire organization, I would like to thank Graham for his contributions over the past year, and we all wish him luck in his next endeavors.” ...See details»
Assembly Biosciences to Present During the 2023 Jefferies …
Led by an accomplished team of leaders in virologic drug development, Assembly Bio is committed to improving outcomes for patients struggling with the serious, chronic impacts of …See details»
Assembly Biosciences Doses First Participant in Phase 1b
Jun 18, 2024 Chronic HBV (cHBV) infection is a leading cause of chronic liver disease and liver transplants globally, with the World Health Organization estimating that over one million …See details»
Assembly Biosciences Expands Senior Leadership Team
INDIANAPOLIS, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious …See details»
Assembly Biosciences Reports Second Quarter 2022 Financial …
Discontinued clinical development of first-generation investigational core inhibitor, VBR, and restructured the organization to prioritize advancement of the company’s more potent next …See details»
Assembly Biosciences to Present Data at Upcoming International ...
May 22, 2024 For more information, visit assemblybio.com. Forward-Looking Statements The information in this press release contains forward-looking statements that are subject to …See details»
Multiple Abstracts Highlighting Assembly Biosciences’ Hepatitis B …
Nov 2, 2020 For more information, visit assemblybio.com. Forward-Looking Statements The information in this press release contains forward-looking statements that are subject to …See details»